Effects of intermittent levetiracetam dosing in a patient with refractory daily seizures

Neurology

Volumn 66, Issue 4, 2006, Pages 590-591

  Friedman, Daniel ^a   French, Jacqueline A ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; ETIRACETAM; LAMOTRIGINE; LORAZEPAM; VALPROIC ACID; ANTICONVULSIVE AGENT; DRUG DERIVATIVE; PIRACETAM;

AGED; ARTICLE; CASE REPORT; DOSE RESPONSE; DRUG INTERMITTENT THERAPY; FEMALE; GENERALIZED EPILEPSY; HUMAN; PRIORITY JOURNAL; SEIZURE; ADULT; DRUG ADMINISTRATION; DRUG COMBINATION; PATHOPHYSIOLOGY;

ADULT; ANTICONVULSANTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; PIRACETAM; SEIZURES;

EID: 33645015647     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000198500.84481.da     Document Type: Article

References (9)

1. Cereghino JJ, Biton V, Abou-Khalil B, et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000;55:236-242.
2. Shorvon SD, Lowenthal A, Janz D, Bielen E, Loiseau P. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia 2000;41:1179-1186.
3. Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia 2000;41:1276-1283.
4. French J, di Nicola S, Arrigo C. Fast and sustained efficacy of levetiracetam during titration and the first 3 months of treatment in refractory epilepsy. Epilepsia 2005;46:1304-7.
5. Glien M, Brandt C, Potschka H, Loscher W. Effects of the novel antiepileptic drug levetiracetam on spontaneous recurrent seizures in the rat pilocarpine model of temporal lobe epilepsy. Epilepsia 2002;43:350-357.
6. Doheny HC, Ratnaraj N, Whittington MA, Jefferys JG, Patsalos PN. Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb L059) in the rat. Epilepsy Res. 1999;34(2-3):161-168.
7. Kasteleijn-Nolst Trenite DG, Marescaux C, Stodieck S, Edelbroek PM, Oosting J. Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam. Epilepsy Res 1996;25:225-230.
8. French J, Arrigo C. Rapid onset of action of levetiracetam in refractory epilepsy patients. Epilepsia 2005;46:324-326.
9. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 2004;101:9861-9866.